Trial Profile
An Open-label, Single-group, Multi-center, Phase II Clinical Trial Evaluating the Effect of Maintenance DCVAC/OvCa After Standard-of-care Therapy in Women With First Relapse of Platinum-sensitive Epithelial Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Oct 2021
Price :
$35
*
At a glance
- Drugs DCVAC OvCa (Primary) ; Carboplatin; Gemcitabine; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors SOTIO
- 26 Mar 2021 Status changed from active, no longer recruiting to completed.
- 03 Nov 2020 Planned primary completion date changed from 1 Oct 2020 to 1 Dec 2020.
- 18 Mar 2020 Planned primary completion date changed from 1 Dec 2020 to 1 Oct 2020.